Adjuvant Therapy Following Resection of Gastroenteropancreatic Neuroendocrine Tumors Provides no Recurrence or Survival Benefit

BACKGROUND AND OBJECTIVES: Lack of high-level evidence supporting adjuvant therapy for patients with resected gastroenteropancreatic neuroendocrine tumors (GEP NETs) warrants evaluation of its non-standard of care use. METHODS: Patients with primary GEP NETs who underwent curative-intent resection a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Surg Oncol
Main Authors: Barrett, James R, Rendell, Victoria, Pokrzywa, Courtney, Lopez-Aguiar, Alexandra G, Cannon, John, Poultsides, George A, Rocha, Flavio, Crown, Angelena, Beal, Eliza, Pawlik, Timothy Michael, Fields, Ryan, Panni, Roheena Z, Smith, Paula, Idrees, Kamran, Cho, Clifford, Beems, Megan, Maithel, Shishir, Weber, Sharon, Abbott, Daniel Erik
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7279693/
https://ncbi.nlm.nih.gov/pubmed/32153032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jso.25896
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados